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Introduction
The major goal of this study is to develop novel single-step CD44 targeting MR imaging probes that can be used to accesses CD44 status of breast tumors. These probes are based on a natural CD44 ligand, hyaluronic acid (also named hyaluronan, HA), which is a non-sulfated linear glucosaminoglycan composed of 2,000 to 25,000 repeating disaccharide subunits of D-glucuronic acid and N-acetylglucosamine. Functionalized HA decorated with multiple gadolinium groups is used as an efficient targeted MR contrast agent. Experiments have been performed in vitro with cultured breast cancer cells and in vivo with preclinical mouse models of human breast cancer. This straightforward targeted imaging approach offers advantages over the traditional multiple-step receptor targeting imaging based on monoclonal antibodies or specific peptides.
Body

Months 1 -2. To synthesize and characterize the hyaluronan (HA)-based contrast agents. Gadolinium contents of the contrast agents will be measured by ICP-MS, and the T1 values will be measured by NMR methods. We will also try to attach a fluorophore tag to the HA backbone for in-vitro cell studies.
During the first year of the project we have synthesized and characterized MR imaging agents using hyaluronic acid (HA) polymer backbones with molecular weights of 16, 31, and 74 kDa. Briefly, HA (200 mg) was dissolved in 2-(N-Morpholino)ethanesulfonic acid buffer (MES 0.1 mol/L, 20 mL, pH 4.75). The carboxyl groups of hyaluronan were activated by the addition of 200mg EDC and 80mg NHS for 30 minutes. 200mg of Ethylenediamine (EDA) was added to this activated hyaluronan solution while pH was maintained at 7.0 with the addition of 1M HCl. The solution was stirred at room temperature for three hours. The product, HA-EDA conjugate, was purified by ultra filtration with an Amicon Centrifugal unit with a 5 or 10kD membrane. Hyaluronan-EDA conjugate was subsequently reacted with 200mg solid DTPA dianhydride in three additions with pH maintained at around 9. This solution was stirred overnight at room temperature. A second batch of 200mg of solid DTPA anhydride was added next day and the reaction proceeded for three more hours. The product, HA-EDA-DTPA conjugate, was purified through ultra filtration with water multiple times. Chelating of gadolinium was performed by the addition of solid GdCl3. This reaction proceeded overnight at pH=7 in 0.1M citric acid buffer. Final product was purified through ultra filtration with water and lyophilized. The gadolinium content of each HA-(EDA-DTPA-Gd) conjugate varied with preparations. A representative gadolinium content of one of these conjugate was 10% as determined by ICPMS, which corresponds to about 70% of the carboxyl groups of HA being attached to EDADTPA-Gd. T1 values of the HA-(EDA-DTPA-Gd) conjugates were measured at 400 MHz at the concentration of in-vivo injection, which is 40mg/ml in deionized water. T1 values of HA-(EDADTPA-Gd) prepared from HA of molecular weight 16kD, 31kD, and 74kD were very comparable in the range from 15.3 ms to 19 ms.
Months 3 -7.
In-vitro studies will be performed on Fluorescent labeled HA probes were synthesized using two alternative strategies. Firstly, Alexa-Fluor488 aminoreactive dye (Invitrogen) was used to modify Hyaluronan-EDA conjugates. The reaction was carried out at room temperature and pH=9 using 3X molar excess of the fluorescent probe. Final product was purified by ultrafiltration using 15 kDa cutoff centrifuge filter devices. In a second approach, a fluorescent hyaluronan (MW 31kD) conjugate was synthesized by reacting hyaluronan with carboxylic reactive BODIPY® FL hydrazide (Molecular Probes D2371) in the presence of EDC and sulfur-NHS. Briefly, 40 mg of HA was reacted with 0.5 mg BODIPY® FL for 0.5 hours in 4 ml of 0.1 M 2-(N-Morpholino)ethanesulfonic acid buffer (MES) in the presence of 10 mg of N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and 10 mg of N-hydroxysuccinimide (NHS) at pH = 5.4. Final product was purified through ultrafiltration. The fluorescent yield was significantly higher for the direct conjugation strategy and, therefore, BODIPY fluorescent HA conjugates (HA-BODIPY) were used in cell studies. FACS experiments were performed with cultured MDA-MB-231 cells (high CD44 expression level) and MCF-7 (low CD44 levels). Scatter plots of the specific fluorescence per cell for MCF-7 and MDA-MB-231 cells labeled with 31 kDA HA-BODIPY are presented in Fig.1 Biodistribtion of the HA-(EDA-DTPA-Gd) contrast agent in vivo was determined by T1 weighted MRI. Initially, the distribution of the contrast was initially limited to the blood vessels. Eventually, all agents were readily excreted through the kidney to the bladder. 74 kDa HA-(EDA-DTPA-Gd) showed greater detail of the circulatory system, especially in the liver and spleen area. Marked washout was seen for 16 kDa HA-(EDA-DTPA-Gd) after 10 minutes while the washout was barely noticeable for the 74kD agent, even at 30 minutes. HA-(EDA-DTPA-Gd) of lower molecular weight appeared to be excreted though the kidney faster than its counter part of higher molecular weight. In addition, HA-(EDA-DTPA-Gd) showed significant uptake by the stomach as early as one hour post injection and 16 kDa HA-(EDA-DTPA-Gd) was absorbed by the stomach faster than 74kD HA-based compound. At 24h, 16 kDa HA-(EDA-DTPA-Gd) was mostly cleared from the stomach into the lower gastrointestinal tract and feces, while significant uptake at the stomach was observed for 74 kDa HA-(EDA-DTPA-Gd). Overall, no adverse reactions such as weight loss and death were observed in mice received HA-(EDADTPA-Gd). Typical MR imaging data are presented in Fig. 2 . 
Key Research Accomplishments
• Paramagnetic HA-based contrast agents were sythetized and characterized • Fluorescent analogs of HA-conjugates were synthetized and tested in in vitro cultured breast cancer cell systems • Pharmacokinetics and biodistribution of the HA-(EDA-DTPA-Gd) agents were defined in vivo in mouse models of human breast cancer.
• In vivo MRI experiments with CD44-positive and CD44-nergative breast cancer models were initiated. 
Reportable Outcomes
Conclusion
The synthesized targeted MR contrast agents demonstrate very good T1 relaxivity that translates to good signal-to-noise ration for MR imaging experiments. Preliminary data suggest preferable binding of the constructs to CD44 expressing breast cancer cells that represent aggressive and potentially most lethal subpopulation in breast cancer. Based on our results HA carriers labeled with both Gd groups for MR imaging and cytotoxic moieties can be used as a unique biocompatible platform for theranostic applications in breast cancer.
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INTRODUCTION
Blood pool contrast agents (BPCA) are desirable in applications such as magnetic resonance angiography (MRA) and tumor microvasculature characterization. In comparison to the commonly used extracellular MRI contrast agents such as gadopentetate dimeglumine, BPCAs exhibit lower leakage into the interstitial space, which minimizes non-specific soft tissue enhancement while prolonging the plasma half-life. These characteristics, in combination with higher relaxivity, can provide better contrast for blood vessels as compared to the standard small molecular extracellular contrast agents such as Gd-DTPA. Relative to normal tissues, solid tumors have enhanced permeability and retention of macromolecules (1). Thus, BPCAs based on macromolecules are also well suited to assess tumor angiogenesis due to these tumor specific properties.
One way to attain prolonged blood circulation time is to design BPCAs as either small molecules that bind to serum albumin, or macromolecules. Currently, there is only one blood pool MRI contrast agent, gadofosveset trisodium, that has been approved for clinical MRA application in Europe (2). Gadofosveset trisodium is also approved by the FDA in the United States to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular complication. Gadofosveset trisodium is a small molecule that reversibly binds to blood serum albumin, which has been proven to be beneficial for MRA applications. However, the properties of macromolecular BPCAs make them better suited for studies aimed at quantifying tumor microvasculature as ambiguities related to reversible albumin binding dynamics are avoided (3) (3). Many macromolecular blood pool agents under current development have shortcomings because of a lack of biocompatibility, toxicity, immunogenicity (4,5), and slow excretion, which eventually can result in the accumulation of toxic Gd 3+ ions (6) (7) (8) . An ideal macromolecular BPCA needs to be large enough so that it has a prolonged blood circulation time and yet small enough to pass through the kidney for unhindered excretion. It has been reported that the vascular permeability in normal tissues of macromolecules with molecular weight greater than 50 kDa is very limited, while the ultrafiltration threshold of the kidney glomerular membrane is below the size of blood serum albumin, a globular protein of 67 kDa (9) . If the molecular size was the only determining factor, it would appear that molecules with molecular weight between 50 and 65 kDa would be most suitable blood pool contrast agent candidates. They would remain in the circulation for an extended period of time, and eventually would be eliminated through the kidneys. However, other factors, such as charge, shape, and hydrophilic/lipophilic balance also affect the extravasation and excretion rates of macromolecules. Generally, amphipathic organic anions with a relatively high molecular weight are eliminated by the liver via metabolism and/or biliary excretion while small and hydrophilic organic anions are excreted into the urine (10).
Relative unhindered clearance through the kidneys may be achieved by using hydrophilic agents with limited protein binding.
Hyaluronan ( (14) . HA is naturally biodegradable since it is digested by a series of enzymatic reactions in-vivo that generate polysaccharides of decreasing sizes, which in principle may facilitate the timely excretion of HA based macromolecular contrast agents. In this study, we used HA of molecular weight 16kDa and 74kDa, which contain approximately 40 and 183 repeating disaccharide subunit respectively, as macromolecular backbone carriers for Gd-DTPA groups. We assessed the enhancement pattern of these HA and Gd-DTPA complex as blood pool agents, and compared them to another common preclinical macromolecular blood pool MRI contrast agent, a bovine serum albumin Gd-DTPA complex (15, 16) .
MATERIALS AND METHODS
Materials
Hyaluronan with molecular weights of 16 and 74 kDa were obtained from Lifecore Biomedical 
In-vivo MRA Studies
All animal experiments were performed in accordance with institutional guidelines.
In-vivo
MRA experiments were performed on a horizontal 9.4T Bruker Biospec spectrometer using a circular volume coil. Mice were anesthetized with an intraperitoneal (i.p.) injection of a ketamine/acepromazine mixture (25 and 2.5 mg/kg, respectively, in saline). For magnetic resonance angiography studies, the tail vein of the mice was catheterized with a 25G needle, which was connected to a T-shape connector that was attached to a HA-(EDA-DTPA-Gd) syringe on one side and a saline syringe (plus 10 international unit Heparin) on the other side.
Each syringe was fitted with a stopcock outside the magnet via a 50 cm polyethylene (PE60) catheter tube. HA-(EDA-DTPA-Gd) was given at a dose of 0.1 mmolGd/kg. For comparison, BSA-(DTPA-Gd) was also given at a dose of 0.1 mmolGd/kg. After a triplanar orthogonal scout imaging of the whole body, coronal MRA images were acquired with a three-dimensional fast Table 1 .
Stability
T 1 values of the HA-(EDA-DTPA-Gd) conjugate based on 16kDa HA in RPMI medium with 10% serum were measure within 5 minutes and up to 5 days at pH 6.3, 7.4, and 9.0. About 5% increase in T 1 was observed at 24 hours in all three pH conditions, and up to 14% increase in T 1 was observed in 5 days, Table 2 .
In-vivo MRI Studies results from BSA-(DTPA-Gd), a well tested blood pool contrast agent given at the same gadolinium dose, are also shown in Figure 2 . Initially, intense and prolonged enhancement was observed in the vasculature for both HA-(EDA-DTPA-Gd) conjugates and BSA-(DTPA-Gd).
However, different distribution and excretion pattern emerged over the next thirty minutes. For HA-(EDA-DTPA-Gd), the distribution of the contrast was initially limited to the blood vessels.
HA-(EDA-DTPA-Gd) prepared from HA of molecular weight 74 kDa showed greater detail of the circulatory system, especially in the liver and spleen. Marked washout was seen for HA-(EDA-DTPA-Gd) prepared from 16 kDa HA after 10 minutes while the washout was barely noticeable for the 74 kDa agent, even at 30 minutes (Figure 1 ). These agents were readily excreted through the kidney to the bladder. HA-(EDA-DTPA-Gd) of lower molecular weight appeared to be excreted through the kidney faster than its counter part of higher molecular weight as shown in Figure 3 , images taken 150 minutes after the injection: aorta and vena cava were barely visible for the agent based on 16 kDa while they were still enhanced for the 74 kDa agent. In contrast, no excretion to the bladder was observed for BSA-(DTPA-Gd), which leaked Half Life of HA-(EDA-DTPA-Gd) Based on 16kDa Figure 6 shows the blood relaxivity of a mouse injected with HA-(EDA-DTPA-Gd) based on 16 kDa HA at various time points after the injection. The change in blood relaxivity as a function of time is best fitted with a two-compartment pharmacokinetic model. The fast phase half time is 12.4 minutes and slow phase half time is 141 minutes. Over 64% of the injected 16 kDa HA-(EDA-DTPA-Gd) was cleared during the fast phase.
DISCUSSION
Since native HA does not have any modifiable amine group, conjugation of DTPA to the carboxyl group of HA was preceded by the introduction of an EDA molecule, a homobifunctional crosslinker with two amine groups. However, following the previously published EDC mediated EDA and HA conjugation methods (17,18), we were not able to obtain a final compound with adequate gadolinium attachment for angiography application. To boost the conjugation between the amine groups of EDA and the carboxyl groups of HA, NHS was added to the HA/EDC solution prior to EDA. Additionally, the amount of EDC added was increased to around two molecular equivalent of HA monomer unit. This process was rather efficient under our experimental conditions, as demonstrated by the gadolinium contents and T 1 of the HA-(EDA-DTPA-Gd) solutions. Although EDA possesses two identical amine groups, the remaining free amine group becomes a weaker base upon the formation of an amide bond at the other amine group with a carboxyl group. The resulting different pK a (6.86 and 9.92
Handbook of Chemistry and Physics) most likely prevented EDA, a homobifunctional crosslinker from inter-or intra-crosslinking two HA carboxyl groups. After one amine group of the EDA molecule is coupled to a carboxyl group of HA molecule, the second EDA amine group with pK a of 9.92 is much less likely to be reactive towards another HA carboxyl group at our reaction condition, pH 7. The amount of EDC added to activate the HA carboxyl group is crucial for the high conjugation rate of EDA to HA. Insufficient amount of EDC drastically decreased the EDA-HA conjugation efficiency, and excess amount of EDC increased the amount of a stable abduct formed between EDC and HA (19) , thus prevented the subsequent conjugation between EDA and HA.
HA-(EDA-DTPA-Gd) prepared from different molecular weights of HA (16 kDa and 74 kDa) showed comparable gadolinium content, T 1 values at the same concentration of 40 mg/ml, and relaxivity (Table 1) . At the same concentration of 40 mg/ml, HA-(EDA-DTPA-Gd) prepared from different molecular weights of HA would contain the same number of disaccharide subunits, and thus the same number of gadolinium attached since the gadolinium content is nearly the same. It appeared that the T 1 relaxation rate of the HA-(EDA-DTPA-Gd) conjugates was determined by the amount of gadolinium present, and not by the molecular weight of the HA carriers at 9.4 Tesla. HA is a linear polymer of repeating disaccharide subunits. An HA molecule assumes an expanded stiffened yet flexible random coil structure in physiological solutions (20) , and does not conform to a well defined globular tertiary structure (21) .
Consequently, molecular weight of HA seemed to have very little effect on the correlation time of the Gd-DTPA groups and the final relaxivity of the whole conjugate in the molecular weight range used, from 16 to 74 kDa.
Nevertheless, the molecular weight of HA does affect the vascular enhancement pattern of HA-(EDA-DTPA-Gd) conjugates. The higher molecular weight agents provided a stronger and more sustained enhancement to the smaller vessels while the lower molecular weight agents exhibited a higher clearance rate through the kidney. BSA-(DTPA-Gd) was not cleared through the kidney since a normal healthy kidney is able to retain all proteins larger than a molecular mass of 60 kDa. Despite a higher molecular weight than BSA, HA-(EDA-DTPA-Gd) prepared from HA of 74 kDa was partially cleared from the kidney most likely due to its linear structure, which results in an elongated random coil tertiary structure compared to globular proteins of similar molecular weight. However, the longer coil that comes with higher molecular weight did result in a slower kidney excretion, compared to the lower molecular weight counterpart as shown in Figure 1 HA-(EDA-DTPA-Gd) based on 16kDa HA is fairly stable in serum containing RPMI medium in various pH as shown in Table 2 . About 5% and 14% increase in the T 1 values were observed at 24 hours and 5 days, which implied that minor amount of gadolinium was lost from the conjugate during these periods. This loss is consistent with the stability commonly observed for the DTPA-Gd macromolecular complex prepared from cyclic DTPA dianhydride (8, 27) . The stability of gadolinium containing blood pool agents may be improved by the use of backbonemodified DTPA analogs, wherein all 5 carboxyl groups remained free for metal binding after conjugation to the macromolecules or macrocyclic chelators (8) .
Stomach and lower gastrointestinal uptake of HA-(EDA-DTPA-Gd) was not expected. In general, liver or spleen were considered the organs that were involved in the HA metabolism (14) . Studies of 3 H labeled HA intravenously injected into sheep showed a concentration dependent half life ranged from 5 to 44 minutes (28) . It was also reported that the clearance of 3 H labeled HA was retarded by prior injection of excess unlabelled HA, and renal excretion with an upper limit of 25 kDa played a negligible part in clearance, and the liver was the main site of uptake (29) . Fluorescence-labeled-hyaluronan with molecular weight of 800 kDa was reported to have a half life of 42 minutes while liver was shown to play a significant rule in its elimination (30) . After intravenous injection of a bolus dose of 14 C-HA in rabbits, it was shown that 98% of the administered dose had disappeared from the systemic circulation within 6 hours after the administration. Within 100 hours, 63% and 20% of the administered dose was excreted and recovered in the respiratory gas (as 14 CO2) or in urine (as low molecular weight HA or monosaccharide fragments). The same authors also reported that the total amount of excretion into bile within 24 hours was reported to be very low, 0.7% of the administered dose, and the total amount of excretion HA into feces, within 100 hours of administration, was also very small, about 0.5% of the administered dose (25) (25) . Research on the effects of size and dose of fluorescein-labeled HA on its metabolism has shown that 60% of the tail vein injected 90 kDa HA accumulated in the liver , while both the 3 kDa and 10 kDa fluorescein-labeled HA were quickly excreted in urine with no accumulation in any tissues (31) . As such, neither HA nor any other gadolinium based MRI agents administered intravenously are known to have any significant gastrointestinal uptake. The gastrointestinal uptake we observed must be due to the unique structure of our HA-(EDA-DTPA-Gd) conjugates. Additionally, we recognize the fact that as a bifunctional chelate, DTPA dianhydride has been known crosslinking amines to form higher molecular weight polymeric aggregates (16) conjugates decreased as the HA molecular weight increased. Uptake in the stomach and lower gastrointestinal tract was observed for the HA-(EDA-DTPA-Gd) conjugates. 
